Read about the progress of individual NINDS PDBP projects and learn about presentations and workshops that are relevant to the PDBP.
A case of M232R genetic Creutzfeldt-Jakob disease with Lewy bodies.

  • Akagi A
  • Iwasaki Y
  • Hashimoto R
  • Aiba I
  • Inukai A
  • Mimuro M
  • Riku Y
  • Miyahara H
  • Kitamoto T
  • Yoshida M
Salivary microR-153 and microR-223 Levels as Potential Diagnostic Biomarkers of Idiopathic Parkinson's Disease.

  • Cressatti M
  • Juwara L
  • Galindez JM
  • Velly AM
  • Nkurunziza ES
  • Marier S
  • Canie O
  • Gornistky M
  • Schipper HM
Circulating Brain-enriched MicroRNAs for detection and discrimination of idiopathic and genetic Parkinson's disease.

  • Ravanidis S
  • Bougea A
  • Papagiannakis N
  • Maniati M
  • Koros C
  • Simitsi AM
  • Bozi M
  • Pachi I
  • Stamelou M
  • Paraskevas GP
  • Kapaki E
  • Moraitou M
  • Michelakakis H
  • Stefanis L
  • Doxakis E
The Associations Between Cognitive Prognosis and Kynurenines Are Modified by the Apolipoprotein ε4 Allele Variant in Patients With Dementia.

  • Ervik AO
  • Hafstad Solvang SE
  • Nordrehaug JE
  • Ueland PM
  • Midttun Ø
  • Hildre A
  • McCann A
  • Nygård O
  • Aarsland D
  • Giil LM
Association of Longitudinal β-Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia.

  • Nedelska Z
  • Schwarz CG
  • Lesnick TG
  • Boeve BF
  • Przybelski SA
  • Lowe VJ
  • Kremers WK
  • Gunter JL
  • Senjem ML
  • Graff-Radford J
  • Ferman TJ
  • Fields JA
  • Knopman DS
  • Petersen RC
  • Jack CR Jr
  • Kantarci K
Alzheimer's disease pathology explains association between dementia with Lewy bodies and APOE-ε4/TOMM40 long poly-T repeat allele variants.

  • Prokopenko I
  • Miyakawa G
  • Zheng B
  • Heikkinen J
  • Petrova Quayle D
  • Udeh-Momoh C
  • Claringbould A
  • Neumann J
  • Haytural H
  • Kaakinen MA
  • Loizidou E
  • Meissner E
  • Bertram L
  • BIOS consortium.
  • Gveric DO
  • Gentleman SM
  • Attems J
  • Perneczky R
  • Arzberger T
  • Muglia P
  • Lill CM
  • Parkkinen L
  • Middleton LT
Lewy body pathology is more prevalent in older individuals with mitochondrial disease than controls.

  • Erskine D
  • Reeve AK
  • Polvikoski T
  • Schaefer AM
  • Taylor RW
  • Lax NZ
  • El-Agnaf O
  • Attems J
  • Gorman GS
  • Turnbull DM
  • Ng YS
Continuous Real-World Gait Monitoring in Idiopathic REM Sleep Behavior Disorder.

  • Del Din S
  • Yarnall AJ
  • Barber TR
  • Lo C
  • Crabbe M
  • Rolinski M
  • Baig F
  • Hu MT
  • Rochester L
Family History Is Associated with Phenotype in Dementia with Lewy Bodies.

  • Vergouw LJM
  • Bosman B
  • van de Beek M
  • Salomé M
  • Hoogers SE
  • van Steenoven I
  • Roks G
  • Bonifati V
  • van Swieten JC
  • Lemstra AW
  • de Jong FJ
Loss of fragile X mental retardation protein precedes Lewy pathology in Parkinson's disease.

  • Tan Y
  • Sgobio C
  • Arzberger T
  • Machleid F
  • Tang Q
  • Findeis E
  • Tost J
  • Chakroun T
  • Gao P
  • Höllerhage M
  • Bötzel K
  • Herms J
  • Höglinger G
  • Koeglsperger T
GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.

  • Johnson PH
  • Weinreb NJ
  • Cloyd JC
  • Tuite PJ
  • Kartha RV

Press releases, workshop summaries, and editorials

Accelerating Medicines Partnership launches data knowledge portal for Parkinson’s disease

Shared platform to catalyze research collaboration toward biomarker discovery to advance the development disease therapies


The Accelerating Medicines Partnership (AMP) program for Parkinson’s disease (PD) has launched a data portal to provide de-identified information collected from 4,298 PD patients and healthy controls to researchers working to develop effective therapies for the disease. The portal enables researchers to study complex data sets and perform genome-wide analyses at a scale previously impossible.

Accelerating Research for Parkinson’s Disease

The Accelerating Medicines Partnership Parkinson's disease (AMP PD) program, launched on Jan 30, 2018, is the most ambitious initiative so far to find a cure for Parkinson's disease. Formed by the US National Institutes of Health (NIH), the US Food and Drug Administration (FDA), five biopharmaceutical and life science companies, and the Michael J. Fox Foundation, this partnership is focused on discovering novel therapeutic targets and on developing biomarkers to help validate existing therapeutic targets for Parkinson's disease.